LHNVD 201
Alternative Names: LHNVD-201Latest Information Update: 28 Sep 2023
At a glance
- Originator Longhorn Vaccines and Diagnostics
- Class COVID-19 vaccines; Influenza virus vaccines; Peptide vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections; Influenza virus infections
Most Recent Events
- 25 Sep 2023 Preclinical immunogenicity data from an animal study on LHNVD 201 in Covid-19 infection and influenza viruse infection released by Longhorn Vaccines and Diagnostics
- 25 Sep 2023 Longhorn Vaccines and Diagnostics plans clinical trials for LHNVD 201
- 19 Sep 2023 Preclinical trials in COVID-2019 infections (Prevention) in USA (unspecified route)